Partner Therapeutics Announces NEJM Publication of Phase 2 eNRGy Trial Results for Zenocutuzumab-Zbco (BIZENGRI®)

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced  that the New England Journal of Medicine (NEJ...

February 06, 2025 | Thursday | News
Akeso, Inc. Completes Patient Enrollment in Global Phase III Trial Evaluating Ivonescimab for First-Line Treatment of Squamous NSCLC

 Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  is excited to announce the completion of patient enrollment in the global Phase III clini...

February 06, 2025 | Thursday | News
AstraZeneca’s Imfinzi® Receives Positive CHMP Recommendation for Limited-Stage Small Cell Lung Cancer Treatment in the EU

AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...

February 05, 2025 | Wednesday | News
Roche Announces FDA Approval of Susvimo® for Diabetic Macular Edema, Offering a Treatment with Fewer Injections

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/...

February 05, 2025 | Wednesday | News
Medidata Advances AI-Powered Clinical Innovation to Transform Patient Care and Drug Development

-Medidata, a Dassault Systèmes brand, reaffirms its vision and commitment to advancing the life sciences industry and transforming patient experie...

February 04, 2025 | Tuesday | News
Vanda Pharmaceuticals and AnaptysBio Enter Exclusive Global License Agreement for Imsidolimab in GPP Treatment

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...

February 04, 2025 | Tuesday | News
PhaseV Partners with Alimentiv to Revolutionize GI Clinical Trials Using Machine Learning

 PhaseV, a pioneer in software and machine learning (ML) for clinical trial optimization, announced  it has entered a strategic partnership with&...

February 04, 2025 | Tuesday | News
Eisai and Biogen Provide Update on Lecanemab’s EU Regulatory Review for Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

February 04, 2025 | Tuesday | News
EMA's CHMP Recommends Opdivo® + Yervoy® for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

 Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

February 03, 2025 | Monday | News
European Commission Approves Vocabria + Rekambys for HIV Treatment in Adolescents Aged 12 and Older

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

February 03, 2025 | Monday | News
Merck's CAPVAXIVE™ Pneumococcal Vaccine Receives Positive CHMP Recommendation for Approval in the European Union

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced  that the Committee for Medicinal Products for Human Use (CHMP) of ...

February 03, 2025 | Monday | News
Roche's PATHWAY® Anti-HER2 Test Gains FDA Approval to Identify HER2-Ultralow Metastatic Breast Cancer Patients for ENHERTU® Treatment

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced  that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® ant...

February 03, 2025 | Monday | News
Celltrion Announces FDA Approval of AVTOZMA® (CT-P47) as Biosimilar to ACTEMRA® for Multiple Indications

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...

January 31, 2025 | Friday | News
Mesoblast Advances U.S. Commercial Launch of Ryoncil® for Pediatric SR-aGvHD, with Key Milestones Ahead

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases,  provided an update on the progres...

January 31, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close